Microbes and Inflammation in Colorectal Cancer
暂无分享,去创建一个
[1] M. Meyerson,et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. , 2013, Cell host & microbe.
[2] C. Sears,et al. Bacterial oncogenesis in the colon. , 2013, Future microbiology.
[3] H. Qin,et al. The role of gut microbiota in the pathogenesis of colorectal cancer , 2013, Tumor Biology.
[4] M. Kipanyula,et al. Signaling pathways bridging microbial-triggered inflammation and cancer. , 2013, Cellular signalling.
[5] E. Cario. Microbiota and innate immunity in intestinal inflammation and neoplasia , 2013, Current opinion in gastroenterology.
[6] F. Shanahan. The colonic microbiota in health and disease , 2013, Current opinion in gastroenterology.
[7] S. Grivennikov. Inflammation and colorectal cancer: colitis-associated neoplasia , 2012, Seminars in Immunopathology.
[8] C. Datz,et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth , 2012, Nature.
[9] Belgin Dogan,et al. Intestinal Inflammation Targets Cancer-Inducing Activity of the Microbiota , 2012, Science.
[10] Francisco Guarner,et al. The gut microbiota in IBD , 2012, Nature Reviews Gastroenterology &Hepatology.
[11] F. Powrie,et al. Identification of a genetic locus controlling bacteria-driven colitis and associated cancer through effects on innate inflammation , 2012, The Journal of experimental medicine.
[12] Bas E Dutilh,et al. A bacterial driver–passenger model for colorectal cancer: beyond the usual suspects , 2012, Nature Reviews Microbiology.
[13] S. Pettersson,et al. Gut microbiota accelerate tumor growth via c-jun and STAT3 phosphorylation in APCMin/+ mice. , 2012, Carcinogenesis.
[14] H. Herfarth,et al. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-κB signaling. , 2012, Immunity.
[15] G. Núñez,et al. Sensing and reacting to microbes through the inflammasomes , 2012, Nature Immunology.
[16] B. Birren,et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. , 2012, Genome research.
[17] Richard A. Moore,et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. , 2012, Genome research.
[18] D. Green,et al. The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. , 2011, Cancer cell.
[19] D. Swinkels,et al. Clinical Importance of Streptococcus gallolyticus infection among colorectal cancer patients: systematic review and meta-analysis. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] R. Schiestl,et al. Intestinal inflammation induces genotoxicity to extraintestinal tissues and cell types in mice , 2011, International journal of cancer.
[21] J. Tschopp,et al. The inflammasome: an integrated view , 2011, Immunological reviews.
[22] P. Woster,et al. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis , 2011, Proceedings of the National Academy of Sciences.
[23] M. Blaser,et al. Antibiotic overuse: Stop the killing of beneficial bacteria , 2011, Nature.
[24] N. Harpaz,et al. Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis‐associated tumorigenesis , 2011, Inflammatory Bowel Diseases.
[25] J. Bertin,et al. A Functional Role for Nlrp6 in Intestinal Inflammation and Tumorigenesis , 2011, The Journal of Immunology.
[26] N. Hall,et al. Towards the Human Colorectal Cancer Microbiome , 2011, PloS one.
[27] M. Chamaillard,et al. Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury , 2011, Proceedings of the National Academy of Sciences.
[28] R. Rappuoli,et al. Helicobacter pylori cytotoxin-associated gene A (CagA) subverts the apoptosis-stimulating protein of p53 (ASPP2) tumor suppressor pathway of the host , 2011, Proceedings of the National Academy of Sciences.
[29] M. Neurath,et al. Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages. , 2011, The Journal of clinical investigation.
[30] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[31] D. Pardoll,et al. Perspective: alpha-bugs, their microbial partners, and the link to colon cancer. , 2011, The Journal of infectious diseases.
[32] C. Jobin,et al. The struggle within: Microbial influences on colorectal cancer , 2011, Inflammatory bowel diseases.
[33] E. Elinav,et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4 , 2010, Proceedings of the National Academy of Sciences.
[34] Keith T. Wilson,et al. Helicobacter pylori and Gastric Cancer: Factors That Modulate Disease Risk , 2010, Clinical Microbiology Reviews.
[35] Shuang Chen,et al. Toll-Like Receptor 2 Signaling Protects Mice from Tumor Development in a Mouse Model of Colitis-Induced Cancer , 2010, PloS one.
[36] Maria Karlsson,et al. Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. , 2010, Cell host & microbe.
[37] F. Marincola,et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18 , 2010, The Journal of experimental medicine.
[38] Gabriel Cuevas-Ramos,et al. Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells , 2010, Proceedings of the National Academy of Sciences.
[39] H. Herfarth,et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer , 2010, The Journal of experimental medicine.
[40] Jongdae Lee,et al. ERK activation drives intestinal tumorigenesis in Apcmin/+ mice , 2010, Nature Medicine.
[41] M. Kastan,et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. , 2010, Immunity.
[42] N. Beauchemin,et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. , 2010, Immunity.
[43] M. Karin,et al. Immunity, Inflammation, and Cancer , 2010, Cell.
[44] A. Gupta,et al. Streptococcus bovis endocarditis, a silent sign for colonic tumour , 2010, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[45] M. Karin,et al. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. , 2010, Cytokine & growth factor reviews.
[46] M. Karin,et al. Inflammation and oncogenesis: a vicious connection. , 2010, Current opinion in genetics & development.
[47] Hua Yu,et al. STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.
[48] Graham M Lord,et al. Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells. , 2009, Cancer cell.
[49] Cynthia L Sears,et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses , 2009, Nature Medicine.
[50] H. Herfarth,et al. Modulation of the Intestinal Microbiota Alters Colitis-Associated Colorectal Cancer Susceptibility , 2009, PloS one.
[51] R. Schiestl,et al. Intestinal mucosal inflammation leads to systemic genotoxicity in mice. , 2009, Cancer research.
[52] Ozge Canli,et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. , 2009, Cancer cell.
[53] D. Golenbock,et al. Induction of Persistent Colitis by a Human Commensal, Enterotoxigenic Bacteroides fragilis, in Wild-Type C57BL/6 Mice , 2009, Infection and Immunity.
[54] H. Tjalsma,et al. Association between Streptococcus bovis and Colon Cancer , 2009, Journal of Clinical Microbiology.
[55] Gabriel Núñez,et al. The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. , 2008, Cancer research.
[56] R. Medzhitov,et al. Innate immune recognition of the indigenous microbial flora , 2008, Mucosal Immunology.
[57] J. Fox,et al. Helicobacter hepaticus promotes azoxymethane‐initiated colon tumorigenesis in BALB/c‐IL10‐deficient mice , 2008, International journal of cancer.
[58] N. Mukaida,et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. , 2008, The Journal of clinical investigation.
[59] E. Kuipers,et al. Migrant communities constitute a possible target population for primary prevention of Helicobacter pylori-related complications in low incidence countries , 2008, Scandinavian journal of gastroenterology.
[60] Wendy S. Garrett,et al. Communicable Ulcerative Colitis Induced by T-bet Deficiency in the Innate Immune System , 2007, Cell.
[61] R. Medzhitov,et al. Regulation of Spontaneous Intestinal Tumorigenesis Through the Adaptor Protein MyD88 , 2007, Science.
[62] R. Kastelein,et al. Swords into plowshares: IL-23 repurposes tumor immune surveillance. , 2007, Trends in immunology.
[63] Carmen Buchrieser,et al. Escherichia coli Induces DNA Double-Strand Breaks in Eukaryotic Cells , 2006, Science.
[64] B. Gulluoglu,et al. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[65] T. Mcclanahan,et al. IL-23 promotes tumour incidence and growth , 2006, Nature.
[66] G. Eslick. Helicobacter pylori infection causes gastric cancer? A review of the epidemiological, meta-analytic, and experimental evidence. , 2006, World journal of gastroenterology.
[67] M. Abreu,et al. TLR Signaling in the Gut in Health and Disease1 , 2005, The Journal of Immunology.
[68] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[69] M. Neurath,et al. IL-6 Signaling Promotes Tumor Growth in Colorectal Cancer , 2005, Cell cycle.
[70] R. Kiesslich,et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. , 2004, Immunity.
[71] C. Hart,et al. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. , 2004, Gastroenterology.
[72] T. Geijtenbeek,et al. Self- and nonself-recognition by C-type lectins on dendritic cells. , 2004, Annual review of immunology.
[73] J. Fox,et al. CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. , 2003, The American journal of pathology.
[74] Cynthia L Sears,et al. Bacteroides fragilis enterotoxin induces c-Myc expression and cellular proliferation. , 2001, Gastroenterology.
[75] S. Pawlowski,et al. Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice. , 2002, Cancer research.
[76] T. Warner,et al. Enterococcus faecalis induces inflammatory bowel disease in interleukin-10 knockout mice. , 2002, The American journal of pathology.
[77] M. Blaser,et al. Helicobacter pylori and gastrointestinal tract adenocarcinomas , 2002, Nature Reviews Cancer.
[78] Rajnish A. Gupta,et al. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 , 2001, Nature Reviews Cancer.
[79] K. Uchida,et al. Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor beta chain and p53 double-knockout mice. , 2001, Cancer research.
[80] R. Garavito,et al. Cyclooxygenases: structural, cellular, and molecular biology. , 2000, Annual review of biochemistry.
[81] D. Kerjaschki,et al. Association between intraepithelial Escherichia coli and colorectal cancer. , 1998, Gastroenterology.
[82] R. DuBois,et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. , 1996, Gastroenterology.
[83] M. Schuler. Aspirin and the risk of colorectal cancer in women. , 1996, The New England journal of medicine.
[84] M. Kondo,et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. , 1995, Cancer research.
[85] S Jothy,et al. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. , 1995, Cancer research.
[86] R. Coffey,et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.
[87] E. Rimm,et al. Aspirin Use and the Risk for Colorectal Cancer and Adenoma in Male Health Professionals , 1994, Annals of Internal Medicine.
[88] C. Williams,et al. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis , 1993, The British journal of surgery.
[89] K. Rajewsky,et al. Interleukin-10-deficient mice develop chronic enterocolitis , 1993, Cell.
[90] S. Piantadosi,et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. , 1993, The New England journal of medicine.
[91] M. Thun,et al. Aspirin use and reduced risk of fatal colon cancer. , 1991, The New England journal of medicine.
[92] B. Marshall,et al. UNIDENTIFIED CURVED BACILLI IN THE STOMACH OF PATIENTS WITH GASTRITIS AND PEPTIC ULCERATION , 1984, The Lancet.
[93] S. Edberg,et al. Association of Streptococcus bovis with carcinoma of the colon. , 1977, The New England journal of medicine.
[94] E. Wynder,et al. Further leads on metabolic epidemiology of large bowel cancer. , 1975, Cancer research.